BOSTON, Nov. 19, 2010 /PRNewswire-FirstCall/ — Solos Endoscopy,
Inc. (Pink Sheets:
SNDY) is pleased to announce that the Company’s management has
approved its 2011 recapitalization plan in order to position itself
for growth over the next twelve months. The recapitalization plan
is designed to increase financial flexibility for Solos and its
shareholders.
The recapitalization plan allows Solos greater flexibility to
utilize the assets of the Company in the future for
corporate purposes; including raising capital, acquisitions or
employee compensation, with limited dilution of existing
stockholder voting rights.
“We are very pleased that the recapitalization allows us to
pursue our existing strategy more aggressively,” stated Bob
Segersten, President of Solos Endoscopy, Inc.
Throughout the remainder of 2010, the Company will continue its
new product development for the MammoView® product line. In
addition, Solos plans to achieve market expansion through its
efforts to meet the requirements of the ISO 13485 standard and
ultimately obtain the CE Mark and the permission to sell medical
devices in the European Union and Canada.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose
mission is to develop and market high quality and innovative
instruments for the screening, diagnosis, treatment and management
of medical conditions. Additional information on its FDA approved
products is available on the Company’s website at:
www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 27E of the
‘/>”/>
SOURCE
